Patents Assigned to Cadent Therapeutics, Inc.
-
Publication number: 20230012073Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.Type: ApplicationFiled: August 10, 2021Publication date: January 12, 2023Applicant: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
-
Patent number: 11541057Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: February 26, 2021Date of Patent: January 3, 2023Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Patent number: 11542264Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.Type: GrantFiled: February 12, 2021Date of Patent: January 3, 2023Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
-
Publication number: 20220274925Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.Type: ApplicationFiled: May 3, 2022Publication date: September 1, 2022Applicant: CADENT THERAPEUTICS, INC.Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
-
Patent number: 11274107Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: December 22, 2017Date of Patent: March 15, 2022Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
-
Patent number: 11236104Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.Type: GrantFiled: January 31, 2020Date of Patent: February 1, 2022Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Patent number: 11116749Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.Type: GrantFiled: July 23, 2018Date of Patent: September 14, 2021Assignee: CADENT THERAPEUTICS, INCInventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
-
Patent number: 10973825Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: December 9, 2016Date of Patent: April 13, 2021Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Publication number: 20200369610Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.Type: ApplicationFiled: August 12, 2020Publication date: November 26, 2020Applicant: CADENT THERAPEUTICS, INC.Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
-
Patent number: 10781174Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.Type: GrantFiled: January 23, 2019Date of Patent: September 22, 2020Assignee: CADENT THERAPEUTICS, INC.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
-
Patent number: 10774064Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.Type: GrantFiled: June 2, 2017Date of Patent: September 15, 2020Assignee: Cadent Therapeutics, Inc.Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
-
Patent number: 10752633Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.Type: GrantFiled: November 8, 2019Date of Patent: August 25, 2020Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
-
Patent number: 10717728Abstract: Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.Type: GrantFiled: June 4, 2019Date of Patent: July 21, 2020Assignee: Cadent Therapeutics, Inc.Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
-
Patent number: 10626122Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.Type: GrantFiled: December 9, 2016Date of Patent: April 21, 2020Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Patent number: 10584131Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.Type: GrantFiled: August 2, 2019Date of Patent: March 10, 2020Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
-
Patent number: 10500205Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: December 9, 2016Date of Patent: December 10, 2019Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
-
Patent number: 10351553Abstract: Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).Type: GrantFiled: March 28, 2018Date of Patent: July 16, 2019Assignee: Cadent Therapeutics, Inc.Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
-
Publication number: 20190152912Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.Type: ApplicationFiled: January 23, 2019Publication date: May 23, 2019Applicant: CADENT THERAPEUTICS, INC.Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
-
Patent number: 10239835Abstract: The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y? are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio?) provided that no more than one oxygen or nitrogen is attached to any carbon.Type: GrantFiled: September 23, 2015Date of Patent: March 26, 2019Assignee: CADENT THERAPEUTICS, INC.Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
-
Publication number: 20180369245Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: ApplicationFiled: December 9, 2016Publication date: December 27, 2018Applicant: Cadent Therapeutics, Inc.Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITE, Christopher FANGER